A Phase 3 interventional study of placebo and tenecteplase in Dysfunctional Hemodialysis Catheters, sponsored by Genentech, Inc.. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-06-03.
Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a Phase III, randomized, double-blind, placebo-controlled study conducted at 37 centers in the United States. 150 subjects ≥ 16 years of age who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
This study's enrollment of 150 is above the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.
First submitted after Genentech, Inc. became part of Hoffmann-La Roche.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tenecteplase
Drug: placebo
For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
Time frame: Visit 1 of HD treatment
Incidence of Targeted Adverse Events (AEs) From Initial Study Drug Administration Through the Start of Visit 2
Targeted AEs were intracranial hemorrhages (ICHs), major bleeding, embolic events, thrombosis, catheter-related bloodstream infections (CRBSIs), and catheter related complications
Time frame: Visits 1 and 2 of consecutive HD treatments
Change in BFR From Baseline to the End of HD at Visit 1
BFR is measured in mL/minute.
Time frame: Visit 1 of HD treatment
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1)
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
Time frame: Visit 2 of consecutive HD treatments
Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2)
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
Time frame: Visit 2 of consecutive HD treatments
| Milestone | Tenecteplase | Placebo |
|---|---|---|
| Started | 74 | 76 |
| Completed | 70 | 71 |
| Not completed | 4 | 5 |
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
| percentage of success | Tenecteplase | Placebo |
|---|---|---|
| Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1 | 21.6 | 5.3 |
Targeted AEs were intracranial hemorrhages (ICHs), major bleeding, embolic events, thrombosis, catheter-related bloodstream infections (CRBSIs), and catheter related complications
| percentage of participants | Tenecteplase | Placebo |
|---|---|---|
| Intracranial hemorrhage | 0 | 0 |
| Major bleeding | 0 | 0 |
| Embolic event | 0 | 0 |
| Thrombosis | 0 | 0 |
| Catheter-related blood stream infection | 0 | 4.0 |
| Catheter-related complication | 0 | 0 |
BFR is measured in mL/minute.
| percentage of participants | Tenecteplase | Placebo |
|---|---|---|
| < 0 mL/min | 8.1 ± 102.97 | 9.3 ± 55.98 |
| 0-24 mL/min | 58.1 | 80.0 |
| 25-49 mL/min | 8.1 | 2.7 |
| 50-99 mL/min | 8.1 | 4.0 |
| 100-149 mL/min | 5.4 | 1.3 |
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
| percentage of success | Tenecteplase | Placebo |
|---|---|---|
| Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Extended Dwell Tenecteplase at Visit 1) | 41.7 | 38.5 |
Treatment success is defined as BFR of ≥300 mL/min and an increase from baseline BFR of ≥25 mL/min at an associated target arterial pressure in the range of 0 to -280 mmHg 30 (±10) minutes prior to the end of HD and at the end of HD.
| percentage of success | Tenecteplase | Placebo |
|---|---|---|
| Percentage of Subjects Who Had Treatment Success With Respect to BFR at Visit 2 (MITT Population With Open-label Tenecteplase at Visit 2) | 11.5 | 34.8 |
Collected over The AEs/SAEs were recorded through the completion of Visit 4.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tenecteplase | — | 1/74 (1.4%) | 12/74 (16.2%) |
| Placebo | — | 5/75 (6.7%) | 11/75 (14.7%) |
| Event | Tenecteplase | Placebo |
|---|---|---|
| SepsisInfections and infestations | 1/74 | 0/75 |
| BacteraemiaInfections and infestations | 0/74 | 1/75 |
| Clostridium Difficile ColitisInfections and infestations | 0/74 | 1/75 |
| PneumoniaInfections and infestations | 0/74 | 1/75 |
| HypoglycaemiaMetabolism and nutrition disorders | 0/74 | 1/75 |
| ConvulsionNervous system disorders | 0/74 | 1/75 |
| Event | Tenecteplase | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 1/74 | 3/75 |
| Thrombosis in DeviceInjury, poisoning and procedural complications | 2/74 | 1/75 |
| VomitingGastrointestinal disorders | 1/74 | 2/75 |
| BacteraemiaInfections and infestations | 0/74 | 2/75 |
| HeadacheNervous system disorders | 0/74 | 2/75 |
| Abdominal Pain UpperGastrointestinal disorders | 1/74 | 1/75 |
| DiarrhoeaGastrointestinal disorders | 1/74 | 0/75 |
| ChillsGeneral disorders | 1/74 | 1/75 |
| PyrexiaGeneral disorders | 1/74 | 1/75 |
| Catheter Related ComplicationGeneral disorders | 1/74 | 0/75 |
| Age, Customized(participants) | Tenecteplase | Placebo | Total |
|---|---|---|---|
| < 17 years | 0 | 0 | 0 |
| >= 17 years to < 65 years | 44 | 51 | 95 |
| >= 65 years | 30 | 24 | 54 |
| Age Continuous(years) | Tenecteplase | Placebo | Total |
|---|---|---|---|
| Mean | 60.8 ± 14.1 | 57.8 ± 16.5 | 59.3 ± 15.3 |
| Sex: Female, Male(Participants) | Tenecteplase | Placebo | Total |
|---|---|---|---|
| Female | 38 | 37 | 75 |
| Male | 36 | 38 | 74 |
No study locations are listed for this record.
The record gives a start of Oct 2006 and a primary completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 6 months after primary completion. A results delay was requested in Jun 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenecteplase